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ABSTRACT
Objective: Acute coronary syndrome (ACS)
encompasses ST segment elevation myocardial
infarction (STEMI), with generally high thrombus
burden and non-ST segment elevation ACS (NSTE-
ACS), with lower thrombus burden. In the setting of
percutaneous coronary intervention (PCI) for ACS,
bivalirudin appears superior to unfractionated heparin
(UFH), driven by reduced major bleeding. Recent trials
suggest that the benefit of bivalirudin may be reduced
with use of transradial access and evolution in
antiplatelet therapy. Moreover, a differential role of
bivalirudin in ACS cohorts is unknown.
Methods: A meta-analysis of randomised trials
comparing bivalirudin and UFH in patients with ACS
receiving PCI, with separate analyses in STEMI and
NSTE-ACS groups. Overall estimates of treatment effect
were calculated with random-effects model.
Results: In 5 trials of STEMI (10 358 patients),
bivalirudin increased the risk of acute stent thrombosis
(ST) (OR 3.62; CI 1.95 to 6.74; p<0.0001) compared
with UFH. Bivalirudin reduced the risk of major
bleeding only when compared with UFH plus planned
glycoprotein IIb/IIIa inhibitors (GPI) (OR 0.49; CI 0.36
to 0.67; p<0.00001). In 14 NSTE-ACS trials (25 238
patients), there was no difference between bivalirudin
and UFH in death, myocardial infarction or ST.
However, bivalirudin reduced the risk of major bleeding
compared with UFH plus planned GPI (OR 0.52; CI
0.43 to 0.62; p<0.00001), or UFH plus provisional GPI
(OR 0.68; CI 0.46 to 1.01; p=0.05). The reduction in
major bleeding with bivalirudin was not related to
vascular access site.
Conclusions: Bivalirudin increases the risk of acute
ST in STEMI, but may confer an advantage over UFH in
NSTE-ACS while undergoing PCI, reducing major
bleeding without an increase in ST.
BACKGROUND
Bivalirudin is an intravenous direct thrombin
inhibitor that is widely used in the setting of
percutaneous coronary intervention (PCI)
for acute coronary syndrome (ACS).1 2
Randomised trials have demonstrated that
bivalirudin is superior to unfractionated
heparin (UFH) in reducing net adverse
cardiac events, mainly due to a reduction in
major bleeding.3–5 This is an important con-
sideration since bleeding related to PCI has
been associated with signiﬁcant deleterious
short-term and long-term consequences.6–8
However, over the past decade, the rates of
major or clinically signiﬁcant bleeding have
KEY QUESTIONS
What is already known about this subject?
▸ The use of bivalirudin during percutaneous cor-
onary intervention (PCI) has been the subject of
much debate recently.
What does this study add?
▸ Our meta-analysis should help clinicians when
selecting a periprocedural anticoagulant in dif-
ferent acute coronary syndrome (ACS) cohorts
undergoing PCI (ie, in ST segment elevation
myocardial infarction (STEMI) vs non-ST
segment elevation (NSTE) ACS).
How might this impact on clinical practice?
▸ This will probably have a great impact on clinical
practice as this meta-analysis suggests that in
patients with STEMI, with generally high throm-
bus burden and with the increasing use of trans-
radial approach and more potent oral antiplatelet
therapy, bivalirudin does not appear to be super-
ior to unfractionated heparin, especially with
provisional use of glycoprotein IIb/IIIa inhibitors
(GPI) as currently recommended. In compari-
son, in patients with NSTE-ACS with lower
thrombus burden, our meta-analysis suggests
that bivalirudin may be superior to unfractio-
nated heparin with provisional GPI use with
regard to bleeding risk, but does not reduce risk
of ischaemic events.
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decreased markedly as a result of innovations in PCI,
including the increasing use of transradial vascular access
and modiﬁcations in adjunct pharmacotherapy. With
respect to the latter, introduction of potent oral antiplate-
let agents have decreased the routine use of glycoprotein
IIb/IIIa inhibitors (GPI) in ACS, with current opinion
favouring their use in patients with large thrombus
burden, insufﬁcient oral antiplatelet therapy, or as a
bailout for complications.9 Perhaps, as a result of this evo-
lution in clinical practice, recent trials suggest that the
previous beneﬁt observed with bivalirudin may be sub-
stantially reduced in the contemporary PCI setting.10 11
Several trials of bivalirudin have reported a small
increase in the risk of myocardial infarction (MI) and/
or stent thrombosis (ST) in patients with ACS undergo-
ing PCI.4 5 12 13 However, the study designs were not dir-
ectly comparable as some of these trials used routine
GPI in the UFH arm compared with provisional GPI use
in the bivalirudin arm.5 12 13 Thus, the net clinical
beneﬁt of bivalirudin use is likely to depend on the rela-
tive risk of ischaemic versus bleeding complications.
The main beneﬁcial effect of potent antithrombotic
therapy would be expected in the setting of large throm-
bus burden. Since ACS comprises of both ST segment
elevation MI (STEMI), with generally high thrombus
burden and non-ST segment elevation ACS
(NSTE-ACS), with lower thrombus burden,14 there is a
need to assess the differential clinical beneﬁt of bivaliru-
din versus UFH in these two groups. We, therefore,
sought to evaluate the effects of bivalirudin compared
with UFH on ischaemic and bleeding outcomes, with
particular focus on the differential role in patients pre-
dominantly with STEMI versus NSTE-ACS.
METHODS
The study was designed according to the PRISMA
(Preferred Reporting Items for Systematic Reviews and
Meta-analyses) Statement.15 Inclusion criteria were ran-
domised controlled trials comparing the effects of biva-
lirudin and UFH, including those with multiple arms.
Trials that involved a bolus of low-molecular-weight
heparin or fondaparinux at baseline and before ran-
domisation were also included. Trials were restricted to
those studying patients predominantly with STEMI or
NSTE-ACS, who underwent PCI. Since ACS encompasses
a wide spectrum of disease, the trials referred to as
STEMI also included some patients with non-STEMI
(NSTEMI), and NSTE-ACS trials also included patients
with stable angina undergoing elective PCI. However,
similar treatment strategies were employed for all
patients in these trials. Exclusion criteria were as follows:
studies that used ﬁbrinolytic therapy, studies that used
balloon angioplasty only, studies that primarily addressed
dosing or timing issues, small studies including ≤50
patients, studies that included patients with stable
angina only, and studies that reported no clinical out-
comes (see online supplementary ﬁgure S1).
The PubMed/Medline, Embase, Scopus and
Cochrane Central Register of Controlled Trials databases
were searched until March 2015, without language
restrictions. Eligible studies were identiﬁed with the fol-
lowing search terms: bivalirudin, Angiomax, Hirulog,
heparin, anticoagulation, primary percutaneous coron-
ary intervention, percutaneous coronary intervention,
coronary intervention, coronary angioplasty, stent, acute
coronary syndrome, myocardial infarction, unstable
angina, randomly, random and randomised controlled
trial. We also searched reference lists of the retrieved
articles to identify other eligible studies. Online oral pre-
sentations and expert slide presentations were also
examined.
Two investigators independently reviewed all titles, or
titles and abstracts from the search results to identify
articles according to fulﬁlment of inclusion criteria.
Selected trials were compared, and disagreement was
resolved by team discussion and consensus. Data extrac-
tion was carried out independently and in duplicate by
the study investigators. Results of data extraction were
then compared, and discrepancies resolved by discus-
sion. If results were incomplete or unclear, the study
authors were contacted. Articles ﬁnally selected for the
review were checked to avoid inclusion of data published
in duplicate. Relevant data was collected on baseline
characteristics, and clinical outcomes at baseline and
end of follow-up. We investigated efﬁcacy end points of
death, MI (including Q wave and non-Q wave), early ST
including acute (<24 h) and subacute (≥24 h to
30 days), all up to 30 days posthospitalisation. Major
bleeding at 30 days posthospitalisation was the safety end
point of interest. The primary outcomes and deﬁnition
of major bleeding for each trial is listed in online sup-
plementary table S1.
Relevant studies were stratiﬁed according to the popu-
lation studied into predominantly STEMI versus pre-
dominantly NSTE-ACS. For the purposes of the
meta-analysis, results are presented for each ACS cohort
independently. Where both ACS cohorts were studied
with distinct results, the respective groups were analysed
separately. Likewise, for trials in which there were three
arms based on GPI use, major bleeding comparisons
were analysed separately.
Statistical analysis
Outcomes are presented as ORs with 95% CIs. Pooled
OR were calculated using a random-effects model by the
method of DerSimonian and Laird.16 Heterogeneity was
assessed using χ2 and I2 tests. All analyses were per-
formed with the intention-to-treat principle. We stratiﬁed
results by key trial characteristics, including type of ACS
(predominantly STEMI vs predominantly NSTE-ACS)
and use of GPIs (predominantly planned in the UFH
arm vs provisional in the bivalirudin arm, provisional in
both arms, or planned in both arms). In sensitivity ana-
lysis, where possible, we included only trials which
included patients predominantly with NSTEMI. We did
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Table 1 Characteristics of predominantly STEMI studies
Study
Patients
(n)
PCI
(%)
Bivalirudin
(n)
UFH
(n) Bivalirudin design UFH design
Female
(%)
Mean
age
(year)
Follow-up
(days)
GPI use (%)
Transradial
(%)Bivalirudin UFH
HORIZONS-AMI,
200813
3602 93 1800 1802 Intravenous bolus
of 0.75 mg/kg
followed by an
infusion of 1.75 mg/
kg/h
Intravenous bolus
of 60 U/kg with
subsequent
boluses targeted
to ACT of 200–
250 s
23 60 30 8 98 6
EUROMAX,
20135
2218 86 1089 1109 Intravenous bolus
of 0.75 mg/kg
followed by an
infusion of 1.75 mg/
kg/h
Intravenous bolus
of 100 U/kg
without GPI or
60 U/kg with GPI
24 62 30 12 69 47
Heat-PPCI,
201410
1812 82 905 907 Intravenous bolus
of 075 mg/kg
followed by infusion
of 175 mg/kg/h. A
rebolus of 03 mg/
kg was
administered if ACT
values were <225 s
Intravenous bolus
of 70 U/kg with
subsequent
boluses if ACT
values were
<200 s
28 63 28 13 15 81
BRIGHT*, 201517 2178 97 729 1449 Intravenous bolus
of 0.75 mg/kg,
followed by a
continuous infusion
of 1.75 mg/kg/h
If ACT was <225 s,
an additional bolus
of 0.3 mg/kg was
added
Intravenous bolus
of 100 U/kg
without GPI or
60 U/kg with GPI,
with subsequent
boluses if ACT
values were
<200 s
18 58 30 4 53 79
BRAVE 4, 201411 548 92 271 277 Intravenous bolus
of 0.75 mg/kg
followed by an
infusion of 1.75 mg/
kg/h
Intravenous bolus
of 70–100 U/kg
with subsequent
boluses
according to ACT
23 61 30 3 6 <1
*The trial involved three arms: bivalirudin alone, UFH alone, and UFH plus GPI.
ACT, activated clotting time; GPI, glycoprotein IIb/IIIa inhibitors; PCI, percutaneous coronary intervention; STEMI, ST segment elevation myocardial infarction; UFH, unfractionated heparin.
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Table 2 Characteristics of predominantly NSTE-ACS studies
Study
Patients (n)/
population
PCI
(%)
Bivalirudin
(n)
UFH
(n) Bivalirudin design UFH design
Female
(%)
Mean
age
(year)
Follow-up
(days)
GPI use (%)
Transradial
(%)Bivalirudin UFH
REPLACE-2,
20033
6010
Elective or
urgent PCI
98 2999 3011 Intravenous bolus of
0.75 mg/kg, followed by
a continuous infusion
of 1.75 mg/kg/h
Intravenous bolus
of 65 U/kg
26 63 30 7 97 0
REPLACE-1,
200420
1056
Elective or
urgent PCI
100 532 524 Intravenous bolus of
0.75 mg/kg, followed by
a continuous infusion
of 1.75 mg/kg/h
Intravenous bolus
of 60–70 U/kg
adjusted to achieve
and maintain an
ACT of 200–300 s
30 64 2 71 73 3
PROTECT-TIMI
30, 200618
857
NSTEMI or
UA
100 284 573 Intravenous bolus of
0.75 mg/kg, followed by
a continuous infusion
of 1.75 mg/kg/h with
additional boluses to
maintain ACT>200 s
Intravenous bolus
of 50 U/kg adjusted
to achieve and
maintain an ACT of
200–250 s
33 60 2 3 99 NR
ACUITY-PCI*,
20074
7789
NSTEMI
100 5228 2561 Intravenous bolus of
01 mg/kg and an
infusion of 025 mg/
kg/h.
An additional
intravenous bolus of
05 mg/kg was
administered before
PCI, and the infusion
was increased to
175 mg/kg/h
Intravenous bolus
of 60 U/kg followed
by an infusion of
12 U/kg/h to
achieve and
maintain an ACT of
200–250 s
27 63 30 53 97 6
ARNO, 200821 850
UA or
elective PCI
86 425 425 Intravenous bolus of
0.75 mg/kg, followed by
a continuous infusion
of 1.75 mg/kg/h
Intravenous bolus
of 100 U/kg with or
without additional
boluses to achieve
an ACT of 250–
300 s
24 69 30 NR NR 2
ISAR-REACT 3,
200822
4570
Elective or
urgent PCI
100 2289 2281 Intravenous bolus of
0.75 mg/kg, followed by
a continuous infusion
of 1.75 mg/kg/h
Intravenous bolus
of 140 U/kg
followed by a
placebo infusion for
the duration of the
procedure
24 67 30 <1 <1 68
Continued
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Table 2 Continued
Study
Patients (n)/
population
PCI
(%)
Bivalirudin
(n)
UFH
(n) Bivalirudin design UFH design
Female
(%)
Mean
age
(year)
Follow-up
(days)
GPI use (%)
Transradial
(%)Bivalirudin UFH
NAPLES,
200923
335
Elective or
urgent PCI
100 167 168 Intravenous bolus of
0.75 mg/kg, followed by
a continuous infusion
of 1.75 mg/kg/h with
additional boluses to
maintain ACT>250 s
Intravenous bolus
of 70 U/kg with
additional boluses
to maintain
ACT>250 s
35 65 30 1 100 3
TENACITY,
201124
383
Elective or
urgent PCI
100 185 198 Intravenous bolus of
0.75 mg/kg, followed by
a continuous infusion
of 1.75 mg/kg/h
Intravenous bolus
of 50 U/kg adjusted
to achieve and
maintain an ACT of
225 s
27 63 30 100 100 NR
ISAR-REACT 4,
201112
1721
NSTEMI
100 860 861 Intravenous bolus of
0.75 mg/kg, followed by
a continuous infusion
of 1.75 mg/kg/h
Intravenous bolus
of 70 U/kg
23 68 30 0 100 <1
ARMYDA-7
BIVALVE,
201225
401
Elective or
urgent PCI
93 198 203 Intravenous bolus of
0.75 mg/kg, followed by
a continuous infusion
of 1.75 mg/kg/h
Intravenous bolus
of 75 U/kg
28 70 30 12 14 2
Deshpande
et al26
101
Elective or
urgent PCI
100 49 52 Intravenous bolus of
0.75 mg/kg, followed by
a continuous infusion
of 1.75 mg/kg/h
Intravenous bolus
of 70 U/kg followed
by an infusion of
20 U/kg/h to
achieve and
maintain an ACT of
200–250 s
13 56 30 100 100 0
SWITCH III,
201319
100
NSTEMI
98 51 49 Intravenous bolus of
0.75 mg/kg, followed by
a continuous infusion
of 1.75 mg/kg/h
Intravenous bolus
of 60 U/kg with
subsequent
boluses to maintain
an ACT>200 s
32 63 30 4 12 68
Xiang et al27 218
UA or
elective PCI
100 110 108 Intravenous bolus of
0.75 mg/kg, followed by
a continuous infusion
of 1.75 mg/kg/h
If ACT was <225 s, an
additional bolus of
0.3 mg/kg was added
Intravenous bolus
of 130 U/kg. If ACT
was <225 s, an
additional bolus of
300 U/kg was
added
17 58 30 1 4 25
Continued
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meta-regression to examine the following relations: (1)
the log-transformed OR of the effect of bivalirudin on
major bleeding and log-transformed OR of the effect of
bivalirudin on mortality, (2) the log-transformed OR of
the effect of bivalirudin on major bleeding and where
possible, the trial reported percentage of the use of
transradial approach.
Publication bias was minimised by a comprehensive lit-
erature search. In addition, a graphical display (funnel
plot) of the size of the treatment effect against the preci-
sion of the trial (1/SE) was used to investigate publica-
tion bias. All tests were two-sided, and statistical
signiﬁcance was ﬁxed at 0.05 level. Analysis was carried
out using Review Manager Software (RevMan V.5.3) and
Stata V.11.2 (StataCorp, College Station, Texas, USA).
RESULTS
We identiﬁed 32 randomised trials comparing the
effects of bivalirudin and UFH, and involving patients
with ACS undergoing PCI. Of these, 19 trials involving
35 596 patients, that met the inclusion and exclusion
criteria, were included in the meta-analysis. The meth-
odological quality of included studies is described in
online supplementary table S2. The primary outcomes
of each trial are listed in online supplementary table
S1. Most trials used a major bleeding deﬁnition based
on either REPLACE-2 or ACUITY. There was no evi-
dence of publication bias having a signiﬁcant effect on
the results (eg, see online supplementary ﬁgures S2
and S3).
The characteristics of individual STEMI trials are
listed in table 1. Five trials enrolled 10 358 patients pre-
dominantly with STEMI,5 10 11 13 17 in which 82–97%
underwent PCI. The characteristics of individual
NSTE-ACS trials are listed in table 2. Four trials predom-
inantly enrolled patients with NSTEMI,4 12 18 19 and 10
trials predominantly enrolled patients with urgent or
elective PCI for unstable or stable angina.3 20–28 In total,
across the 14 NSTE-ACS trials, 24 979 (98.9%) of 25 238
patients underwent PCI. Bivalirudin doses were similar
across all included trials (intravenous bolus of 0.75 mg/
kg followed by an infusion of 1.75 mg/kg/h). UFH
doses ranged between 50 U/kg, as in TENACITY24 and
PROTECT-TIMI 30,18 and up to 140 U/kg, as in
ISAR-REACT 3,22 with a median dose of 70 U/kg across
all included trials.
In STEMI, there was no difference in the risk of death
(OR 0.91; CI 0.72 to 1.15; p=0.42) (ﬁgure 1A), MI (OR
1.44; CI 0.90 to 2.30; p=0.12) (ﬁgure 1B), any ST (OR
1.65; CI 0.89 to 3.07; p=0.11) (ﬁgure 2A), or subacute
ST (OR 0.86; CI 0.47 to 1.60; p=0.64) (ﬁgure 2C)
between the two drugs. As compared with UFH, bivaliru-
din increased the risk of acute ST (OR 3.62; CI 1.95 to
6.74; p<0.0001) (ﬁgure 2B). Major bleeding was less
with bivalirudin plus provisional GPI compared with
UFH plus planned GPI (OR 0.49; CI 0.36 to 0.67;
p<0.00001) (ﬁgure 3A). However, there was no
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difference in the risk of major bleeding when both
drugs were combined with provisional GPI (OR 0.98; CI
0.59 to 1.63; p=0.93) (ﬁgure 3B).
In NSTE-ACS, there was no difference between bivalir-
udin and UFH in the risk of death (OR 0.96; CI 0.64 to
1.45; p=0.86), MI (OR 1.09; CI 0.98 to 1.21; p=0.11), or
any ST (OR 1.20; CI 0.84 to 1.70; p=0.31) (ﬁgure 4).
Two NSTE-ACS trials reported no signiﬁcant difference
between bivalirudin and UFH in the risk of acute and
subacute ST.21 25 Bivalirudin plus provisional GPI
Figure 1 Death, myocardial infarction with bivalirudin versus unfractionated heparin (UFH) in predominantly ST segment
elevation myocardial infarction (STEMI) studies; (A) death, (B) myocardial infarction.
Figure 2 Any, acute and subacute stent thrombosis with bivalirudin versus unfractionated heparin (UFH) in predominantly ST
segment elevation myocardial infarction (STEMI) studies; (A) any stent thrombosis, (B) acute stent thrombosis (<24 h), and (C)
subacute stent thrombosis (≥24 h to 30 days).
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reduced the risk of major bleeding compared with UFH
plus planned GPI (OR 0.52; CI 0.43 to 0.62; p<0.00001)
(ﬁgure 5A). Also, bivalirudin reduced the risk of major
bleeding compared with UFH, with provisional use of
GPI in both arms (OR 0.68; CI 0.46 to 1.01; p=0.05)
(ﬁgure 5B). However, there was no difference in the
risk of major bleeding when either drug was combined
with planned GPI (OR 0.94; CI 0.57 to 1.53; p=0.79)
(ﬁgure 5C). The results observed in NSTE-ACS were
also observed within the group of trials that enrolled
patients predominantly with NSTEMI (see online sup-
plementary ﬁgure S4).
There was no signiﬁcant relation between the reduc-
tion in bleeding with bivalirudin and mortality across all
trials (p=0.96; see online supplementary ﬁgure S5). Also,
there was no signiﬁcant relation between the reduction
in bleeding with bivalirudin and the use of transradial
approach across all trials (p=0.49; see online supplemen-
tary ﬁgure S6), in predominantly STEMI trials (p=0.61),
or in predominantly NSTE-ACS trials (p=0.15).
DISCUSSION
The use of bivalirudin during PCI has been the subject
of much debate recently. Most evidence of beneﬁt was
obtained when bivalirudin monotherapy was compared
with a combination therapy of UFH plus GPI.
Therefore, the differing beneﬁts seen with bivalirudin
and UFH in PCI may be in part related to the differen-
tial rates of GPI use. In this meta-analysis of 19 trials
involving 35 596 patients, we found that bivalirudin may
confer an advantage over UFH in patients with
NSTE-ACS undergoing PCI, while this was not so in
patients with STEMI. This difference is attributable to
substantially increased risk of acute ST in STEMI-treated
patients and not in NSTE-ACS. Moreover, bivalirudin
use was associated with a signiﬁcant reduction in major
bleeding in NSTE-ACS but not in STEMI, when com-
pared with UFH and provisional GPI use in both arms.
There was no signiﬁcant difference in the incidence of
death, MI, or any ST between bivalirudin and UFH
treated patients for both types of ACS.
The potential advantage of bivalirudin on bleeding
risk was signiﬁcantly affected by the strategy for con-
comitant GPI use. Overall, bivalirudin monotherapy con-
sistently reduced the risk of bleeding in both ACS
cohorts compared with UFH plus planned GPI. In con-
trast, when the use of GPI was provisional in bivalirudin
and UFH arms, a beneﬁt of bivalirudin use was observed
in NSTE-ACS but not in STEMI. This may be in part
due to the fact that the studies in NSTE-ACS included
ISAR-REACT 322 (ﬁgure 5B), in which a very high bolus
dose of UFH (140 U/kg) was used, resulting in more
bleeding outcomes in the UFH arm. Also, the transra-
dial approach was used more in STEMI than in
NSTE-ACS trials (43% vs 15%, p=0.09), an approach
associated with overall reduced bleeding29 30 and there-
fore, perhaps negating the reduction in bleeding that
may have been observed with bivalirudin had a transfe-
moral approach been used. However, in contrast to what
one might expect, our meta-analysis suggests that the
relative reduction in major bleeding with bivalirudin was
probably non-vascular access site related and did not
seem to depend on the transradial approach use across
all included trials (p=0.49), or in independent ACS
cohorts (STEMI (p=0.61) versus NSTE-ACS (p=0.15)).
In ﬁve NSTE-ACS studies, when GPI was planned in
both arms, there was no difference in the risk of major
bleeding.
Our ﬁndings are further supported by the recently
conducted MATRIX trials, which showed that transradial
compared with transfemoral access reduced net adverse
clinical events through a reduction in all-cause mortality
and major bleeding in 8404 patients with ACS
Figure 3 Major bleeding with bivalirudin versus unfractionated heparin (UFH) in predominantly ST segment elevation
myocardial infarction (STEMI) studies; (A) glycoprotein IIb/IIIa inhibitors (GPI) predominantly provisional in the bivalirudin arm
versus planned use in the heparin arm, and (B) provisional GPI use in both arms.
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undergoing PCI.31 In a parallel trial to assess antithrom-
botic effects, about 95% of 7213 patients with ACS (56%
STEMI and 44% NSTE-ACS) were also randomised to
bivalirudin or UFH with provisional GPI use (4.6% in
bivalirudin group vs 26% in UFH group).32 Reduction in
all-cause mortality was seen with bivalirudin (1.7% vs
2.3%; risk ratio (RR) 0.71; 95% CI 0.51 to 0.99), which
was probably due to a reduction in major bleeding (1.4%
vs 2.5%; RR 0.55; 95% CI 0.39 to 0.78), importantly with
an independent bivalirudin impact on bleeding not
related to the vascular access site. The rate of deﬁnite ST
was higher with bivalirudin compared with UFH (1.0% vs
0.6%; RR 1.71; 95% CI 1.00 to 2.93). In contrast to our
ﬁndings, although there has not been yet a published
subgroup analysis of the MATRIX antithrombotic trial,
the authors state that the ﬁndings were consistent across
various subgroups (ie, STEMI vs NSTE-ACS).
In theory, continued bivalirudin infusion after PCI
might decrease the risk of acute ST in patients with
STEMI. The MATRIX optical coherence tomography
(OCT) substudy will provide data on whether prolonged
bivalirudin infusion, compared with intraprocedural-only
Figure 4 Death, myocardial infarction and any stent thrombosis with bivalirudin versus unfractionated heparin (UFH) in
predominantly non-ST segment elevation acute coronary syndrome (NSTE-ACS) studies; (A) death, (B) myocardial infarction,
and (C) any stent thrombosis.
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administration in patients undergoing PCI, reduces the
initial increase in ST (residual thrombosis on stent
struts) as evaluated by OCT at the end of PCI and at
3–5 days follow-up.33
Our ﬁndings, which incorporate data from recent
trials, should help clinicians when selecting a periproce-
dural anticoagulant in different ACS cohorts undergoing
PCI. In patients with STEMI, with generally high throm-
bus burden and with the increasing use of transradial
approach and more potent oral antiplatelet therapy, biva-
lirudin does not appear to be superior to UFH, espe-
cially with provisional use of GPI as currently
recommended. In comparison, in patients with
NSTE-ACS with lower thrombus burden, our
meta-analysis suggests that bivalirudin may be superior to
UFH with provisional GPI use with regard to bleeding
risk, but does not reduce risk of ischaemic events. The
results of future trials of bivalirudin should provide more
understanding of the clinical outcomes with this antith-
rombotic drug in different ACS cohorts undergoing PCI.
Study limitations
Our meta-analysis has several limitations. First, most
trials in NSTE-ACS included a considerable proportion
of patients with stable angina undergoing elective PCI.
This cohort was also included in our study, as the trials
did not report a separate analysis for the ACS cohort.
That being said, similar treatment strategies were
allowed for patients with stable angina in these trials.
Second, we were unable to gain full access to the
MATRIX antithrombotic trial32 subgroup results to
include in the meta-analysis section. Third, UFH doses
were different across the trials, which may have impacted
on differential bleeding outcomes in the ACS cohorts
studied. Fourth, the trials included had differences in
vascular access, drug design and deﬁnitions. Finally, the
results of this meta-analysis are derived from study-level
data and not from patient-level data. Additionally, one
trial had been presented but not published.21 Also,
many of the trials included were open label with a
potential for high performance bias. Finally, most of the
large studies were conducted in developed western
countries and thus, may not be generalisable to other
healthcare settings.
CONCLUSIONS
Although in STEMI, bivalirudin is associated with an
increased risk of acute ST, it may confer an advantage
Figure 5 Major bleeding with bivalirudin versus unfractionated heparin (UFH) in predominantly non-ST segment elevation acute
coronary syndrome (NSTE-ACS) studies; (A) glycoprotein IIb/IIIa inhibitors (GPI) predominantly provisional in the bivalirudin arm
versus planned use in the heparin arm, (B) provisional GPI use in both arms, and (C) planned GPI use in both arms.
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over UFH in patients with NSTE-ACS undergoing PCI,
with a reduction in non-vascular access site major bleed-
ing and without an increase in ST. Large randomised
studies are needed to elucidate more precisely the
optimal PCI-related antithrombotic regimen for patients
presenting with STEMI and NSTE-ACS in the contem-
porary era.
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